Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses

Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effec...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Sci Rep
Prif Awduron: Jiang, Zhaohui, Fu, Lingyun, Xu, Yini, Hu, Xiaoxia, Yang, Hong, Zhang, Yanyan, Luo, Hong, Gan, Shiquan, Tao, Ling, Liang, Guiyou, Shen, Xiangchun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156511/
https://ncbi.nlm.nih.gov/pubmed/32286474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-63498-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg